2025-03-07 |
2025-03-05 |
V
Vente
|
Clark James David
SVP, Cont & Chief Acct Officer
Dirigeant
|
7 513
-47.2%
66,35
498 488 USD
|
7 513
-47.2%
|
66,35
|
498 488 USD
|
|
2025-02-19 |
2025-02-18 |
A
Achat
|
Mahoney Michael F
Administrateur non-exécutif
|
30 000
+320.6%
66,70
2 001 000 USD
|
30 000
+320.6%
|
66,70
|
2 001 000 USD
|
|
2024-05-02 |
2024-05-02 |
A
Achat
|
LUDWIG EDWARD J
Administrateur non-exécutif
|
1 000
+4.8%
53,88
53 879 USD
|
1 000
+4.8%
|
53,88
|
53 879 USD
|
|
2024-05-02 |
2024-05-02 |
A
Achat
|
Mahoney Michael F
Administrateur non-exécutif
|
9 181
+5246.3%
54,49
500 294 USD
|
9 181
+5246.3%
|
54,49
|
500 294 USD
|
|
2024-02-16 |
2024-02-16 |
V
Vente
|
Shah Prem S
EVP and Pres-Pharm, Consumer W
Dirigeant
|
29 473
-42.6%
76,95
2 267 947 USD
|
29 473
-42.6%
|
76,95
|
2 267 947 USD
|
|
2023-11-06 |
2023-11-03 |
A
Achat
|
LUDWIG EDWARD J
Administrateur non-exécutif
|
2 000
+10.7%
70,47
140 930 USD
|
2 000
+10.7%
|
70,47
|
140 930 USD
|
|
2023-08-04 |
2023-08-03 |
V
Vente
|
Clark James David
SVP, Cont & Chief Acct Officer
Dirigeant
|
23 128
-83.1%
74,94
1 733 212 USD
|
23 128
-83.1%
|
74,94
|
1 733 212 USD
|
|
2023-08-04 |
2023-08-03 |
V
Vente
|
Clark James David
SVP, Cont & Chief Acct Officer
Dirigeant
|
2 631
-8.6%
74,79
196 792 USD
|
2 631
-8.6%
|
74,79
|
196 792 USD
|
|
2023-05-05 |
2023-05-03 |
A
Achat
|
Lynch Karen S
President and CEO
Administrateur exécutif
|
14 000
+3.4%
69,75
976 567 USD
|
14 000
+3.4%
|
69,75
|
976 567 USD
|
|
2022-12-16 |
2022-12-15 |
VP
Vente planifiée
|
Moriarty Thomas M
EVP & General Counsel
Dirigeant
|
36 490
-5.7%
98,24
3 584 869 USD
|
36 490
-5.7%
|
98,24
|
3 584 869 USD
|
|
2022-12-16 |
2022-12-15 |
VP
Vente planifiée
|
Moriarty Thomas M
EVP & General Counsel
Dirigeant
|
100 976
-14.2%
98,40
9 936 311 USD
|
100 976
-14.2%
|
98,40
|
9 936 311 USD
|
|
2022-08-05 |
2022-08-04 |
VP
Vente planifiée
|
Lotvin Alan
EVP&President-PharmacyServices
Dirigeant
|
22 541
-17.1%
104,00
2 344 264 USD
|
22 541
-17.1%
|
104,00
|
2 344 264 USD
|
|
2022-08-05 |
2022-08-03 |
VP
Vente planifiée
|
Lotvin Alan
EVP&President-PharmacyServices
Dirigeant
|
50 501
-31.6%
98,00
4 949 098 USD
|
50 501
-31.6%
|
98,00
|
4 949 098 USD
|
|
2022-08-05 |
2022-08-03 |
VP
Vente planifiée
|
Lotvin Alan
EVP&President-PharmacyServices
Dirigeant
|
70 398
-39.2%
98,00
6 899 004 USD
|
70 398
-39.2%
|
98,00
|
6 899 004 USD
|
|
2022-08-05 |
2022-08-03 |
VP
Vente planifiée
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Dirigeant
|
9 546
-22.9%
100,00
954 600 USD
|
9 546
-22.9%
|
100,00
|
954 600 USD
|
|
2022-04-12 |
2022-04-08 |
VP
Vente planifiée
|
Shah Prem S
EVP and Co-President of Retail
Dirigeant
|
3 130
-6.7%
105,00
328 650 USD
|
3 130
-6.7%
|
105,00
|
328 650 USD
|
|
2022-04-12 |
2022-04-08 |
VP
Vente planifiée
|
Shah Prem S
EVP and Co-President of Retail
Dirigeant
|
4 103
-8.1%
105,00
430 815 USD
|
4 103
-8.1%
|
105,00
|
430 815 USD
|
|
2022-04-12 |
2022-04-08 |
VP
Vente planifiée
|
Shah Prem S
EVP and Co-President of Retail
Dirigeant
|
5 719
-10.9%
105,00
600 495 USD
|
5 719
-10.9%
|
105,00
|
600 495 USD
|
|
2022-04-12 |
2022-04-08 |
VP
Vente planifiée
|
Shah Prem S
EVP and Co-President of Retail
Dirigeant
|
3 157
-6.3%
105,00
331 485 USD
|
3 157
-6.3%
|
105,00
|
331 485 USD
|
|
2022-04-12 |
2022-04-08 |
VP
Vente planifiée
|
Shah Prem S
EVP and Co-President of Retail
Dirigeant
|
845
-1.8%
105,00
88 725 USD
|
845
-1.8%
|
105,00
|
88 725 USD
|
|
2022-04-06 |
2022-04-05 |
VP
Vente planifiée
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Dirigeant
|
5 941
-15.6%
100,00
594 100 USD
|
5 941
-15.6%
|
100,00
|
594 100 USD
|
|
2022-04-06 |
2022-04-04 |
VP
Vente planifiée
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Dirigeant
|
12 032
-24.0%
100,13
1 204 764 USD
|
12 032
-24.0%
|
100,13
|
1 204 764 USD
|
|
2022-04-06 |
2022-04-04 |
VP
Vente planifiée
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Dirigeant
|
27 166
-35.1%
100,13
2 720 132 USD
|
27 166
-35.1%
|
100,13
|
2 720 132 USD
|
|
2022-04-06 |
2022-04-04 |
VP
Vente planifiée
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Dirigeant
|
16 161
-24.4%
100,13
1 618 201 USD
|
16 161
-24.4%
|
100,13
|
1 618 201 USD
|
|
2022-03-18 |
2022-03-17 |
V
Vente
|
Shah Prem S
EVP and Co-President of Retail
Dirigeant
|
2 935
-4.7%
106,65
313 018 USD
|
2 935
-4.7%
|
106,65
|
313 018 USD
|
|
2022-03-18 |
2022-03-17 |
V
Vente
|
Shah Prem S
EVP and Co-President of Retail
Dirigeant
|
1 689
-2.8%
106,65
180 132 USD
|
1 689
-2.8%
|
106,65
|
180 132 USD
|
|
2022-03-17 |
2022-03-15 |
V
Vente
|
Moriarty Thomas M
EVP & General Counsel
Dirigeant
|
51 361
-5.8%
105,00
5 392 905 USD
|
51 361
-5.8%
|
105,00
|
5 392 905 USD
|
|
2022-02-11 |
2022-02-10 |
A
Achat
|
LUDWIG EDWARD J
Administrateur non-exécutif
|
1 000
+5.8%
105,90
105 904 USD
|
1 000
+5.8%
|
105,90
|
105 904 USD
|
|
2022-02-04 |
2022-02-03 |
VP
Vente planifiée
|
Brennan Troyen A
EVP and Chief Medical Officer
Dirigeant
|
47 937
-25.7%
110,00
5 273 070 USD
|
47 937
-25.7%
|
110,00
|
5 273 070 USD
|
|
2022-02-02 |
2022-02-01 |
VP
Vente planifiée
|
Lotvin Alan
EVP&President-PharmacyServices
Dirigeant
|
21 386
-25.9%
106,50
2 277 566 USD
|
21 386
-25.9%
|
106,50
|
2 277 566 USD
|
|
2022-02-01 |
2022-01-28 |
VP
Vente planifiée
|
Clark James David
SVP, Cont & Chief Acct Officer
Dirigeant
|
6 059
-25.7%
109,00
660 431 USD
|
6 059
-25.7%
|
109,00
|
660 431 USD
|
|
2022-01-28 |
2022-01-27 |
VP
Vente planifiée
|
Roberts Jonathan C
EVP & Chief Operating Officer
Dirigeant
|
68 482
-39.0%
107,50
7 361 815 USD
|
68 482
-39.0%
|
107,50
|
7 361 815 USD
|
|
2021-11-05 |
2021-11-03 |
VP
Vente planifiée
|
Roberts Jonathan C
EVP & Chief Operating Officer
Dirigeant
|
108 870
-50.4%
95,00
10 342 650 USD
|
108 870
-50.4%
|
95,00
|
10 342 650 USD
|
|
2021-11-03 |
2021-11-01 |
V
Vente
|
Brennan Troyen A
EVP and Chief Medical Officer
Dirigeant
|
28 159
-16.9%
90,00
2 534 310 USD
|
28 159
-16.9%
|
90,00
|
2 534 310 USD
|
|
2021-10-28 |
2021-10-26 |
VP
Vente planifiée
|
Brennan Troyen A
EVP and Chief Medical Officer
Dirigeant
|
80 802
-36.9%
88,00
7 110 576 USD
|
80 802
-36.9%
|
88,00
|
7 110 576 USD
|
|
2021-10-28 |
2021-10-26 |
V
Vente
|
Brennan Troyen A
EVP and Chief Medical Officer
Dirigeant
|
1 955
-0.9%
88,00
172 040 USD
|
1 955
-0.9%
|
88,00
|
172 040 USD
|
|
2021-06-29 |
2021-06-28 |
VP
Vente planifiée
|
Lotvin Alan
EVP&President-PharmacyServices
Dirigeant
|
2 781
-4.4%
83,67
232 686 USD
|
2 781
-4.4%
|
83,67
|
232 686 USD
|
|
2021-06-17 |
2021-06-15 |
VP
Vente planifiée
|
Brennan Troyen A
EVP and Chief Medical Officer
Dirigeant
|
67 552
-32.1%
86,00
5 809 472 USD
|
67 552
-32.1%
|
86,00
|
5 809 472 USD
|
|
2021-06-08 |
2021-06-07 |
VP
Vente planifiée
|
Finke Daniel P
EVP/Pres, Health Care Benefits
Dirigeant
|
37 594
-61.7%
86,60
3 255 640 USD
|
37 594
-61.7%
|
86,60
|
3 255 640 USD
|
|
2021-05-12 |
2021-05-10 |
VP
Vente planifiée
|
Moriarty Thomas M
EVP & General Counsel
Dirigeant
|
109 469
-100.0%
86,00
9 414 334 USD
|
109 469
-100.0%
|
86,00
|
9 414 334 USD
|
|
2021-05-10 |
2021-05-07 |
VP
Vente planifiée
|
Brennan Troyen A
EVP and Chief Medical Officer
Dirigeant
|
9 477
-6.1%
84,00
796 068 USD
|
9 477
-6.1%
|
84,00
|
796 068 USD
|
|
2021-05-06 |
2021-05-04 |
VP
Vente planifiée
|
Boratto Eva C
EVP & CFO
Dirigeant
|
4 905
-4.1%
80,00
392 400 USD
|
4 905
-4.1%
|
80,00
|
392 400 USD
|
|
2021-04-23 |
2021-04-21 |
VP
Vente planifiée
|
Moriarty Thomas M
EVP & General Counsel
Dirigeant
|
2 420
-100.0%
77,00
186 340 USD
|
2 420
-100.0%
|
77,00
|
186 340 USD
|
|
2021-04-23 |
2021-04-21 |
VP
Vente planifiée
|
Moriarty Thomas M
EVP & General Counsel
Dirigeant
|
101 003
-97.7%
77,00
7 777 231 USD
|
101 003
-97.7%
|
77,00
|
7 777 231 USD
|
|
2021-04-01 |
2021-03-31 |
VP
Vente planifiée
|
Clark James David
SVP, Cont & Chief Acct Officer
Dirigeant
|
5 350
-42.5%
76,00
406 600 USD
|
5 350
-42.5%
|
76,00
|
406 600 USD
|
|
2021-03-30 |
2021-03-29 |
VP
Vente planifiée
|
Moriarty Thomas M
EVP & General Counsel
Dirigeant
|
62 943
-100.0%
76,15
4 793 109 USD
|
62 943
-100.0%
|
76,15
|
4 793 109 USD
|
|
2021-03-29 |
2021-03-26 |
VP
Vente planifiée
|
MERLO LARRY J
Administrateur non-exécutif
|
270 650
-34.1%
74,73
20 225 675 USD
|
270 650
-34.1%
|
74,73
|
20 225 675 USD
|
|
2021-03-29 |
2021-03-26 |
VP
Vente planifiée
|
Roberts Jonathan C
EVP & Chief Operating Officer
Dirigeant
|
73 433
-99.1%
74,49
5 470 024 USD
|
73 433
-99.1%
|
74,49
|
5 470 024 USD
|
|
2021-03-23 |
2021-03-19 |
VP
Vente planifiée
|
Moriarty Thomas M
EVP & General Counsel
Dirigeant
|
49 211
-73.0%
74,15
3 648 996 USD
|
49 211
-73.0%
|
74,15
|
3 648 996 USD
|
|
2021-03-17 |
2021-03-16 |
VP
Vente planifiée
|
Boratto Eva C
EVP & CFO
Dirigeant
|
18 882
-21.0%
74,68
1 410 108 USD
|
18 882
-21.0%
|
74,68
|
1 410 108 USD
|
|
2021-02-17 |
2021-02-17 |
A
Achat
|
LUDWIG EDWARD J
Administrateur non-exécutif
|
3 000
+26.5%
72,00
216 000 USD
|
3 000
+26.5%
|
72,00
|
216 000 USD
|
|
2021-01-21 |
2021-01-19 |
VP
Vente planifiée
|
MERLO LARRY J
President and CEO
Administrateur exécutif
|
62 893
-10.7%
77,00
4 842 761 USD
|
62 893
-10.7%
|
77,00
|
4 842 761 USD
|
|
2021-01-13 |
2021-01-12 |
VP
Vente planifiée
|
Bisaccia Lisa
EVP and Chief HR Officer
Dirigeant
|
25 177
-35.1%
77,00
1 938 629 USD
|
25 177
-35.1%
|
77,00
|
1 938 629 USD
|
|
2021-01-12 |
2021-01-08 |
VP
Vente planifiée
|
Lotvin Alan
EVP and President-CVS Caremark
Dirigeant
|
25 836
-75.5%
75,00
1 937 700 USD
|
25 836
-75.5%
|
75,00
|
1 937 700 USD
|
|
2021-01-12 |
2021-01-08 |
VP
Vente planifiée
|
Brennan Troyen A
EVP and Chief Medical Officer
Dirigeant
|
58 896
-56.1%
75,00
4 417 200 USD
|
58 896
-56.1%
|
75,00
|
4 417 200 USD
|
|
2020-11-17 |
2020-11-13 |
VP
Vente planifiée
|
Lotvin Alan
EVP and President-CVS Caremark
Dirigeant
|
7 138
-47.1%
70,00
499 660 USD
|
7 138
-47.1%
|
70,00
|
499 660 USD
|
|
2020-11-12 |
2020-11-10 |
VP
Vente planifiée
|
Flum Joshua Matthew
EVP, ENT STRATEGY & DIGITAL
Dirigeant
|
21 460
-46.2%
70,00
1 502 200 USD
|
21 460
-46.2%
|
70,00
|
1 502 200 USD
|
|
2020-05-28 |
2020-05-26 |
VP
Vente planifiée
|
Clark James David
SVP, Cont & Chief Acct Officer
Dirigeant
|
270
-5.6%
65,00
17 550 USD
|
270
-5.6%
|
65,00
|
17 550 USD
|
|
2020-05-28 |
2020-05-26 |
VP
Vente planifiée
|
Mayhew Jonathan E.
EVP - Transformation
Dirigeant
|
10 556
-69.0%
65,00
686 140 USD
|
10 556
-69.0%
|
65,00
|
686 140 USD
|
|
2020-05-13 |
2020-05-11 |
A
Achat
|
Lotvin Alan
EVP and President-CVS Caremark
Dirigeant
|
5 000
+49.2%
63,14
315 675 USD
|
5 000
+49.2%
|
63,14
|
315 675 USD
|
|
2020-04-30 |
2020-04-28 |
VP
Vente planifiée
|
Clark James David
SVP, Cont & Chief Acct Officer
Dirigeant
|
6 234
-56.4%
65,00
405 210 USD
|
6 234
-56.4%
|
65,00
|
405 210 USD
|
|
2020-04-01 |
2020-03-30 |
VP
Vente planifiée
|
Clark James David
SVP, Cont & Chief Acct Officer
Dirigeant
|
3 030
-23.7%
60,00
181 800 USD
|
3 030
-23.7%
|
60,00
|
181 800 USD
|
|
2020-01-17 |
2020-01-15 |
VP
Vente planifiée
|
MERLO LARRY J
President and CEO
Administrateur exécutif
|
266 476
-37.9%
74,79
19 929 740 USD
|
266 476
-37.9%
|
74,79
|
19 929 740 USD
|
|
2020-01-10 |
2020-01-08 |
VP
Vente planifiée
|
Roberts Jonathan C
EVP & Chief Operating Officer
|
57 563
-56.1%
72,63
4 180 801 USD
|
57 563
-56.1%
|
72,63
|
4 180 801 USD
|
|
2019-11-20 |
2019-11-18 |
VP
Vente planifiée
|
Lynch Karen S
EVP & Pres, Aetna Bus Unit
|
80 143
-65.7%
75,00
6 010 725 USD
|
80 143
-65.7%
|
75,00
|
6 010 725 USD
|
|
2019-11-06 |
2019-11-04 |
VP
Vente planifiée
|
Brennan Troyen A
EVP and Chief Medical Officer
Dirigeant
|
23 604
-21.9%
68,00
1 605 072 USD
|
23 604
-21.9%
|
68,00
|
1 605 072 USD
|
|
2019-10-01 |
2019-09-30 |
VP
Vente planifiée
|
Flum Joshua Matthew
EVP, ENT STRATEGY & DIGITAL
|
17 703
-49.0%
63,00
1 115 289 USD
|
17 703
-49.0%
|
63,00
|
1 115 289 USD
|
|
2019-09-13 |
2019-09-12 |
VP
Vente planifiée
|
Boratto Eva C
EVP & CFO
|
8 130
-14.7%
65,00
528 450 USD
|
8 130
-14.7%
|
65,00
|
528 450 USD
|
|
2019-03-11 |
2019-03-11 |
A
Achat
|
BROWN C DAVID II
|
10 000
+9.9%
53,18
531 800 USD
|
10 000
+9.9%
|
53,18
|
531 800 USD
|
|
2019-03-11 |
2019-03-11 |
A
Achat
|
AGUIRRE FERNANDO
|
1 900
+13.3%
53,59
101 821 USD
|
1 900
+13.3%
|
53,59
|
101 821 USD
|
|
2019-03-11 |
2019-03-08 |
A
Achat
|
LUDWIG EDWARD J
|
2 000
+37.2%
52,80
105 600 USD
|
2 000
+37.2%
|
52,80
|
105 600 USD
|
|
2019-03-11 |
2019-03-08 |
A
Achat
|
DORMAN DAVID W
Administrateur non-exécutif
|
9 600
+8.5%
52,71
506 016 USD
|
9 600
+8.5%
|
52,71
|
506 016 USD
|
|
2019-03-04 |
2019-03-01 |
A
Achat
|
AGUIRRE FERNANDO
|
3 410
+31.2%
58,29
198 769 USD
|
3 410
+31.2%
|
58,29
|
198 769 USD
|
|
2019-03-04 |
2019-03-01 |
A
Achat
|
LUDWIG EDWARD J
|
4 000
+290.3%
58,27
233 080 USD
|
4 000
+290.3%
|
58,27
|
233 080 USD
|
|
2019-03-01 |
2019-03-01 |
V
Vente
|
Clark James David
SVP, Cont & Chief Acct Officer
Dirigeant
|
1 664
-19.4%
58,14
96 745 USD
|
1 664
-19.4%
|
58,14
|
96 745 USD
|
|